Consensus or Controversy? Clinical Investigators Provide
Perspectives on the Current and Future Management of Prostate
Cancer — Part 2: Our one-on-one interview with Dr Smith featuring
emerging research and cases from his practice.
Recent advances in the treatment of nonmetastatic CRPC
(00:00)
Effect of PSA doubling time on prognosis for patients with
nonmetastatic disease (3:01)
PSA doubling time and clinical decision-making for patients
with M0 disease (7:59)
Counseling patients with nonmetastatic disease about goals of
therapy and expected side effects (10:26)
Similarities and differences in the design, entry criteria and
efficacy endpoints among the ARAMIS, SPARTAN and PROSPER trials
(13:25)
Comparison of the side-effect profiles of apalutamide,
enzalutamide and darolutamide (15:35)
Counseling patients receiving long-term ADT about
treatment-related fatigue (18:35)
Comparison of primary (metastasis-free survival) and secondary
outcomes among the ARAMIS, SPARTAN and PROSPER trials (20:32)
Choosing among darolutamide, apalutamide and enzalutamide
(22:45)
SPARTAN trial: PFS2 improvement with apalutamide for high-risk
nonmetastatic CRPC (24:42)
Outcomes, tolerability and appropriate use of abiraterone in
combination with prednisone (26:27)
Similarities and differences in the design, entry criteria and
efficacy endpoints between the LATITUDE (ADT with
abiraterone/prednisone or placebo) and ARCHES (ADT with
enzalutamide or placebo) trials for patients with metastatic HSPC
(29:46)
Key clinical and practical factors guiding the selection of
docetaxel versus abiraterone/prednisone for metastatic HSPC
(35:39)
Perspective on the intensification of therapy for patients with
metastatic HSPC and suboptimal responses to ADT (39:08)
Spectrum and frequency of somatic and germline DNA repair gene
mutations in prostate cancer; activity of PARP inhibitors in
patients with metastatic CRPC (40:57)
Incidence of MSI-H/dMMR molecular phenotype in patients with
prostate cancer; indications for testing and current role of immune
checkpoint inhibitors (46:37)
Results of a Phase II prospective trial of
lutetium-177-PSMA-617 theranostics in metastatic CRPC (50:42)
Novel immune checkpoint inhibitor-based combinations for
metastatic CRPC (56:08)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.